The Valley Desk

Clinical trial reportThe British journal of dermatologyPublished

Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
The British journal of dermatology
Published
Subject terms
Humans; Psoriasis; Antibodies, Monoclonal; Treatment Outcome; Severity of Illness Index; Double-Blind Method; Adult; Antibodies, Monoclonal, Humanized; Adalimumab
PubMed ID
37022762
Added to directory
Source checked

Report a correction or request removal